guest ::
| Home > Publications database > Circulating inflammatory biomarkers, adipokines and breast cancer risk-a case-control study nested within the EPIC cohort. > print |
| Home > Publications database > Circulating inflammatory biomarkers, adipokines and breast cancer risk-a case-control study nested within the EPIC cohort. > print |
| 001 | 179588 | ||
| 005 | 20240229145548.0 | ||
| 024 | 7 | _ | |a 10.1186/s12916-022-02319-y |2 doi |
| 024 | 7 | _ | |a pmid:35430795 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC9014562 |2 pmc |
| 024 | 7 | _ | |a altmetric:126809842 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-00766 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Cairat, Manon |b 0 |
| 245 | _ | _ | |a Circulating inflammatory biomarkers, adipokines and breast cancer risk-a case-control study nested within the EPIC cohort. |
| 260 | _ | _ | |a Heidelberg [u.a.] |c 2022 |b Springer |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1650875390_22269 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Inflammation has been hypothesized to play a role in the development and progression of breast cancer and might differently impact breast cancer risk among pre and postmenopausal women. We performed a nested case-control study to examine whether pre-diagnostic circulating concentrations of adiponectin, leptin, c-reactive protein (CRP), tumour necrosis factor-α, interferon-γ and 6 interleukins were associated with breast cancer risk, overall and by menopausal status.Pre-diagnostic levels of inflammatory biomarkers were measured in plasma from 1558 case-control pairs from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. We used conditional logistic regression to estimate the odds ratios (ORs) of breast cancer at blood collection, per one standard deviation increase in biomarker concentration.Cases were diagnosed at a mean age of 61.4 years on average 8.6 years after blood collection. No statistically significant association was observed between inflammatory markers and breast cancer risk overall. In premenopausal women, borderline significant inverse associations were observed for leptin, leptin-to-adiponectin ratio and CRP [OR= 0.89 (0.77-1.03), OR= 0.88 (0.76-1.01) and OR= 0.87 (0.75-1.01), respectively] while positive associations were observed among postmenopausal women [OR= 1.16 (1.05-1.29), OR= 1.11 (1.01-1.23), OR= 1.10 (0.99-1.22), respectively]. Adjustment for BMI strengthened the estimates in premenopausal women [leptin: OR = 0.83 (0.68-1.00), leptin-to-adiponectin ratio: OR = 0.80 (0.66-0.97), CRP: OR = 0.85 (0.72-1.00)] but attenuated the estimates in postmenopausal women [leptin: OR = 1.09 (0.96-1.24), leptin-to-adiponectin ratio: OR = 1.02 (0.89-1.16), CRP: OR = 1.04 (0.92-1.16)].Associations between CRP, leptin and leptin-to-adiponectin ratio with breast cancer risk may represent the dual effect of obesity by menopausal status although this deserves further investigation. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Anthropometry |2 Other |
| 650 | _ | 7 | |a Biomarkers |2 Other |
| 650 | _ | 7 | |a Breast cancer |2 Other |
| 650 | _ | 7 | |a Inflammation |2 Other |
| 650 | _ | 7 | |a Menopausal status |2 Other |
| 650 | _ | 7 | |a Adipokines |2 NLM Chemicals |
| 650 | _ | 7 | |a Adiponectin |2 NLM Chemicals |
| 650 | _ | 7 | |a Biomarkers |2 NLM Chemicals |
| 650 | _ | 7 | |a Leptin |2 NLM Chemicals |
| 650 | _ | 7 | |a C-Reactive Protein |0 9007-41-4 |2 NLM Chemicals |
| 650 | _ | 2 | |a Adipokines |2 MeSH |
| 650 | _ | 2 | |a Adiponectin |2 MeSH |
| 650 | _ | 2 | |a Biomarkers |2 MeSH |
| 650 | _ | 2 | |a Body Mass Index |2 MeSH |
| 650 | _ | 2 | |a Breast Neoplasms: diagnosis |2 MeSH |
| 650 | _ | 2 | |a Breast Neoplasms: epidemiology |2 MeSH |
| 650 | _ | 2 | |a C-Reactive Protein: metabolism |2 MeSH |
| 650 | _ | 2 | |a Case-Control Studies |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Leptin |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Prospective Studies |2 MeSH |
| 650 | _ | 2 | |a Risk Factors |2 MeSH |
| 700 | 1 | _ | |a Rinaldi, Sabina |b 1 |
| 700 | 1 | _ | |a Navionis, Anne-Sophie |b 2 |
| 700 | 1 | _ | |a Romieu, Isabelle |b 3 |
| 700 | 1 | _ | |a Biessy, Carine |b 4 |
| 700 | 1 | _ | |a Viallon, Vivian |b 5 |
| 700 | 1 | _ | |a Olsen, Anja |b 6 |
| 700 | 1 | _ | |a Tjønneland, Anne |b 7 |
| 700 | 1 | _ | |a Fournier, Agnès |b 8 |
| 700 | 1 | _ | |a Severi, Gianluca |b 9 |
| 700 | 1 | _ | |a Kvaskoff, Marina |b 10 |
| 700 | 1 | _ | |a Fortner, Renée T |0 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2 |b 11 |u dkfz |
| 700 | 1 | _ | |a Kaaks, Rudolf |0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a |b 12 |u dkfz |
| 700 | 1 | _ | |a Aleksandrova, Krasimira |b 13 |
| 700 | 1 | _ | |a Schulze, Matthias B |b 14 |
| 700 | 1 | _ | |a Masala, Giovanna |b 15 |
| 700 | 1 | _ | |a Tumino, Rosario |b 16 |
| 700 | 1 | _ | |a Sieri, Sabina |b 17 |
| 700 | 1 | _ | |a Grasso, Chiara |b 18 |
| 700 | 1 | _ | |a Mattiello, Amalia |b 19 |
| 700 | 1 | _ | |a Gram, Inger T |b 20 |
| 700 | 1 | _ | |a Olsen, Karina Standahl |b 21 |
| 700 | 1 | _ | |a Agudo, Antonio |b 22 |
| 700 | 1 | _ | |a Etxezarreta, Pilar Amiano |b 23 |
| 700 | 1 | _ | |a Sánchez, Maria-Jose |b 24 |
| 700 | 1 | _ | |a Santiuste, Carmen |b 25 |
| 700 | 1 | _ | |a Barricarte, Aurelio |b 26 |
| 700 | 1 | _ | |a Monninkhof, Evelyn |b 27 |
| 700 | 1 | _ | |a Hiensch, Anouk E |b 28 |
| 700 | 1 | _ | |a Muller, David |b 29 |
| 700 | 1 | _ | |a Merritt, Melissa A |b 30 |
| 700 | 1 | _ | |a Travis, Ruth C |b 31 |
| 700 | 1 | _ | |a Weiderpass, Elisabete |b 32 |
| 700 | 1 | _ | |a Gunter, Marc J |b 33 |
| 700 | 1 | _ | |a Dossus, Laure |0 0000-0003-2716-5748 |b 34 |
| 773 | _ | _ | |a 10.1186/s12916-022-02319-y |g Vol. 20, no. 1, p. 118 |0 PERI:(DE-600)2131669-7 |n 1 |p 118 |t BMC medicine |v 20 |y 2022 |x 1741-7015 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:179588 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2021-01-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-29 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-29 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2021-01-29 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2021-01-29 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BMC MED : 2021 |d 2022-11-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2021-02-14T16:19:46Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2021-02-14T16:19:46Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Open peer review |d 2021-02-14T16:19:46Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-25 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-25 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b BMC MED : 2021 |d 2022-11-25 |
| 920 | 1 | _ | |0 I:(DE-He78)C020-20160331 |k C020 |l C020 Epidemiologie von Krebs |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C020-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|